In this line, the acetylcholinesterase inhibitor rivastigmine reversed the abnormality of sensorimotor integration, as evaluated by testing short-latency afferent inhibition, in patients affected by Alzheimer’s disease (Di Lazzaro et al., 2005). The gene discussed is ACHE; the disease is Alzheimer disease.